Background: Several single nucleotide polymorphisms (SNPs), related to antiplatelet drug efficacy, are known to be associated with adverse events during antiplatelet therapy. However, their added value to clinical risk prediction models is uncertain, limiting their possible clinical application. The current objective was to determine whether genetic variation has added value to a validated clinical risk prediction model for ST-segment elevation myocardial infarction (STEMI) patients.
Methods:
The study population included 1, 286 patients presenting with STEMI, treated with primary percutaneous coronary intervention and dual antiplatelet therapy with aspirin and clopidogrel. A validated risk score, containing age, Killip class, culprit vessel, three-vessel disease, troponin T, left ventricular ejection fraction and heart rate, was evaluated with and without two SNPs (COX1 -842A>G and CYP2C19*2), previously associated with antiplatelet drug response. Improvement of the model was determined by change in the c-index of the ROC curves and net reclassification improvement (NRI).
Results:
During a median follow-up of 35 months, 84 patients suffered from a primary event (cardiovascular mortality or hospitalisation for heart failure). Using the clinical risk score the event rate of the low risk category (score 0-2, n = 535) was 2.1%, of the intermediate group (score 3-5, n = 609) 5.1% and of the high risk group (score ≥ 6, n = 142) 25.4%. Carriage of two or more risk alleles of the two SNPs was significantly associated with the primary endpoint after adjustment for the clinical parameters with a hazard ratio of 2.3 (95% CI 1.2-4.4), p = 0.01.Addition of the genetic markers to the model resulted in a small shift in the event rates of the different categories, 1.9%, 4.6% and 23.1% respectively. The genetic data did not significantly improve the c-index, from 0.779 to 0.781, p = 0.80. Also, no significant improvement of the reclassification was observed, NRI 0.01, p = 0.71.
Conclusion:
Although the SNPs in COX1 and CYP2C19 are significantly associated with adverse events, even after adjustment for clinical factors, they do not provide an added value to a clinical risk score for the risk stratification of STEMI patients. Purpose: Obstructive sleep apnea (OSA) has a strong association with hypertension (HT), diabetes mellitus (DM) and coronary artery disease (CAD). It is an increasingly prevalent condition, affecting 24% of men and 9% of women, although it is underdiagnosed. The purpose of our study was to evaluate the prevalence and prognostic impact of OSA in patients (P) with acute coronary syndrome (ACS).
Methods:
Prospective study of P < 70 years of age, admitted for ACS with Killip-Kimball (KK) ≤ 2.Screening of OSA was performed during hospitalization with apnea-link (AL), along with anthropometric, clinical and analytical evaluation. P with positive AL did polysomnography study (PSG) for diagnostic confirmation and onset of treatment with continuous positive airway pressure (CPAP) device. A follow-up (FU) (7.0 ± 4.0 months) regarding MACCE was done.
Results: From a population of 342 P admitted for ACS along 12 months, 19% (n = 65) were included (86% men; age 57.8 ± 8.6 years). AL was positive in 49.2% (n = 32) of P, with the PSG confirming the diagnosis in 65.6% (n = 21) of those. CPAP treatment was started in these P. OSA P more often had DM (34.4% vs 17.1%; p = 0.038) with higher levels of insulin and C-peptide; HT (77.3% vs 53.6%; p = 0.066); previous history of CAD (31.8% vs 12.2%; p = 0.059) with angioplasty (22.7% vs 7.3%; p = 0.080) and chronic heart failure (18.2% vs 2.4%; p = 0.028). OSA P had higher body mass index (31.0 ± 5.5 vs 26.5 ± 3.6; p = 0.002); cervical (42.7 ± 3.7 vs 40.8 ± 12.3; p = 0.003) and abdominal (108.2 ± 14.2 vs 94.9 ± 10.0; p = 0.002) perimeter. No differences were found regarding arterial blood gases, CAD severity or left ventricle systolic function. During FU and after CPAP treatment has been started no differences were found in MACCE incidence (7.3% vs 9.1%; p = 0.804).
Conclusions: OSA has a very high prevalence in P with ACS (32.3%), comparing with the general population. Apnea-link showed to be a good in-hospital screening method due to his high negative predictive value and easy feasibility. OSA association with metabolic syndrome was confirmed and systematic screening should be done in these patients. The treatment with CPAP might improve the prognosis of these patients in an independently way. Purpose: despite the frequent recourse to the postoperative therapy and advancement in adjuvant pharmacological therapy, readmission rates for recurrent acute coronary syndrome (ACS) remain very high. The aim of this study was to evaluate clinical predictors of recurrent acute coronary syndromes (≥ 3) in patients with a history of prior myocardial infarction and that undergo percutaneous coronary intervention (ICP) by ACS.
Methods: Retrospective analysis of 942 patients (pts) (mean age 66 ± 11, 73 men, 34% with diabetes) with a previous history of myocardial infarction (MI) and that held ICP by new ACS. By logistic regression analysis, have been assessed clinical predictors for occurrence of a new ACS after ICP. Results: After a median of 529 (426-941) follow-up days after ICP, there were 147 (15, 6%) recurrent MI: type 1 MI in 90 pts, type 2 in 2 pts, type 4b in 54 pts and type 5 in 1 pts. By univariate analyse, pts with recurrent ACS presented more previous history of diabetes mellitus (42% vs 33%; p = 0, 058), of ICP or coronary surgery (68% vs 59%; p = 0, 035 and 35% vs 22%; p = 0, 001, respectively), increased peripheral artery disease frequency (23% vs 12%; p = 0, 001) and multivessel disease (48% vs 37%; p = 0, 013). Figure 1 illustrates the independent clinical predictors of recurrent MI. Pts with recurrent MI have higher rates of global mortality (25% vs 11%; p < 0, 001) or cardiovascular mortality (18% vs 5%; p < 0, 001).
Conclusions:
the results obtained pointed out that the pts that present ACS (≥ 3) constitute a particular subgroup with more extensive cardiac and non-cardiac atheromatous disease, with more intervention and with worse prognosis, justifying a more agressively strategy prevention of disease progression.
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Successful reperfusion of epicardial arteries not necessarily results in peripheral myocardial perfusion. Local delivery of GP IIb/IIIa inhibitors (GPI) into the infarct related artery has been proposed to achieve further clinical efficacy, with the hypothesis that a higher local concentration can be reached through direct intracoronary bolus administration as compared to standard intravenous application. Clinical trials comparing intracoronary (IC) with intravenous (IV) abciximab bolus have shown conflicting results, with some studies being clearly underpowered for evaluation of hard clinical endpoints. Aim of the present study was therefore the comparison between IC and IV abciximab administration on mortality and MACEs in patients with ACS undergoing PCI, through a meta-analysis of all available clinical trials, including the most recently published large randomized study.
Five studies were selected, reporting clinical outcomes at short term, for a total of 3313 patients, 1762 treated with intracoronary (IC) bolus administration and 1551 treated with intravenous bolus administration (IV). The analysis for the short-term combined clinical endpoint revealed that incidence of MACE was significantly lower in the IC group than in the IV group (OR = 0.66; 95% CI 0.51-0.84; p = 0.001). Interestingly, subgroup analysis showed that most of the benefit observed in the IC group, over the IV group, was coming from those studies with a main baseline LVEF < 50% (OR = 0.33 95%CI 0.18-0.59 vs OR = 0.91 95%CI 0.64-1.29; p = 0.003).
Analysis of studies reporting long-term outcome confirmed that incidence of MACE was significantly lower in the IC group than in the IV group (OR = 0.52; 95% CI 0.30-0.91; p = 0.023). Interestingly, subgroup analysis showed that most of the benefit observed in the IC group, over the IV group, was coming from those studies with a main baseline EF < 50% (Eitel/Thiele 2008, Iversen 2011) (OR = 0.38 95%CI 0.23-0.63 p < 0.001).
In conclusion, the present work provides evidence of a clinical benefit of abciximab administration through intracoronary bolus, as compared to intravenous bolus. This results are confirmed at both short-term and long-term outcome analysis. Of note, our data indicate that a still major benefit from IC abciximab bolus over the IV route is obtained in high risk patients, as those with more depressed baseline LVEF. Moreover, no relevant differences were found in terms of bleeding complications between the two administration routes. Background: Hemorrhagic complications are strongly linked with subsequent adverse outcomes in acute coronary syndrome (ACS) patients. Various risk scores (RS) are available to estimate the bleeding risk in these patients.
Aims:
To compare the predictive accuracy of the three contemporary bleeding RS in ACS.
Methods:
We studied 4500 consecutive patients with ACS. For each patient, the ACTION, CRUSADE, and Mehran et al bleeding RS were calculated. We assessed their performance either for the prediction of their own major bleeding events or to predict the TIMI serious (major and minor) bleeding episodes in the overall population, in patients with non-ST elevation ACS (NSTEACS) and in those with ST-elevation myocardial infarction (STEMI) patients. Calibration (Hosmer-Lemeshow test) and discrimination (c-statistic) for the three RS were computed and compared. We used the concept of net reclassification improvement (NRI) to compare the incremental prognostic value of using a particular RS over the remaining scores in predicting the TIMI serious bleeding.
Results:
The best predictive accuracy was obtained by the CRUSADE score either for the prediction of its own major bleeding events (c-statistic = 0.80, 0.791, and 0.81 for the entire sample, for STEMI, and for NSTEACS patients, respectively) or to predict the TIMI serious bleed occurrence (c-statistic = 0.741, 0.738, and 0.745 for the whole population, for STEMI and NSTEACS patients, respectively). The lowest bleeding rates observed in patients classified as low risk corresponded to the CRUSADE RS. All scores performed modestly in patients who did not undergo coronariography (all c-statistic < 0.70). The CRUSADE score was significantly superior to the ACTION model in predicting the TIMI serious bleeding occurrence in terms of NRI overall and by ACS subgroups (p < 0.05). Overall, the CRUSADE RS exhibited better calibration for predicting the TIMI serious bleeding compared to the ACTION and Mehran et al scores (Hosmer-Lemeshow p-values of 0.26, 0.13, and 0.07, respectively).
Conclusion:
The CRUSADE score represents, among the more contemporary bleeding RS, the most accurate and reliable quantitative clinical tool in STEACS and STEMI patients. We encourage the utilization of the CRUSADE index for bleeding risk stratification purposes in daily clinical practice and in ACS outcome studies. The performance of the three more contemporary bleeding RS is modest in those patients who received conservative management.
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